Harvard Bioscience Announces CFO Transition
Harvard Bioscience (NASDAQ: HBIO) announced the resignation of CFO and Treasurer Jennifer Cote, effective upon the filing of the Company's Q1 2025 10-Q report, expected by May 12, 2025. The company has appointed Mark Frost as Interim CFO and Treasurer.
Frost, who has been consulting for HBIO since January 2025, brings over 30 years of financial and executive management experience. His previous roles include CFO positions at Fathom, Argon Medical Devices, Analogic, AngioDynamics, and AMRI. He began his career at General Electric and holds a BA in International Relations and Economics from Colgate University.
CEO Jim Green expressed confidence in Frost's capabilities to lead the finance team in the current challenging market environment, while acknowledging Cote's contributions, particularly in leading the recent ERP system consolidation project.
Harvard Bioscience (NASDAQ: HBIO) ha annunciato le dimissioni della CFO e Tesoriere Jennifer Cote, con effetto al deposito del rapporto 10-Q del primo trimestre 2025 della società, previsto per il 12 maggio 2025. L'azienda ha nominato Mark Frost come CFO e Tesoriere ad interim.
Frost, che collabora con HBIO da gennaio 2025, porta con sé oltre 30 anni di esperienza nella gestione finanziaria ed esecutiva. Le sue precedenti esperienze includono ruoli di CFO presso Fathom, Argon Medical Devices, Analogic, AngioDynamics e AMRI. Ha iniziato la sua carriera alla General Electric e ha conseguito una laurea in Relazioni Internazionali ed Economia presso la Colgate University.
Il CEO Jim Green ha espresso fiducia nelle capacità di Frost di guidare il team finanziario nell'attuale contesto di mercato difficile, riconoscendo al contempo i contributi di Cote, in particolare nella conduzione del recente progetto di consolidamento del sistema ERP.
Harvard Bioscience (NASDAQ: HBIO) anunció la renuncia de la CFO y Tesorera Jennifer Cote, efectiva al momento de la presentación del informe 10-Q del primer trimestre de 2025 de la compañía, que se espera para el 12 de mayo de 2025. La empresa ha nombrado a Mark Frost como CFO y Tesorero interino.
Frost, quien ha estado asesorando a HBIO desde enero de 2025, aporta más de 30 años de experiencia en gestión financiera y ejecutiva. Sus roles anteriores incluyen posiciones de CFO en Fathom, Argon Medical Devices, Analogic, AngioDynamics y AMRI. Comenzó su carrera en General Electric y tiene una licenciatura en Relaciones Internacionales y Economía de la Universidad de Colgate.
El CEO Jim Green expresó confianza en las capacidades de Frost para liderar el equipo financiero en el actual entorno de mercado desafiante, al tiempo que reconoció las contribuciones de Cote, especialmente en la dirección del reciente proyecto de consolidación del sistema ERP.
하버드 바이오사이언스 (NASDAQ: HBIO)는 CFO이자 재무 담당 이사인 제니퍼 코트(Jennifer Cote)가 사임한다고 발표했으며, 이는 2025년 1분기 10-Q 보고서 제출 시점부터 효력이 발생하며, 보고서는 2025년 5월 12일로 예상됩니다. 회사는 마크 프로스트(Mark Frost)를 임시 CFO 및 재무 담당 이사로 임명했습니다.
프로스트는 2025년 1월부터 HBIO에 자문을 제공해왔으며, 30년 이상의 재무 및 경영 경험을 보유하고 있습니다. 그의 이전 경력으로는 Fathom, Argon Medical Devices, Analogic, AngioDynamics 및 AMRI에서 CFO로 일한 경험이 있습니다. 그는 제너럴 일렉트릭에서 경력을 시작했으며, 콜게이트 대학교에서 국제관계 및 경제학 학사 학위를 취득했습니다.
CEO 짐 그린(Jim Green)은 현재의 어려운 시장 환경에서 재무 팀을 이끌 수 있는 프로스트의 능력에 대한 신뢰를 표명하며, 최근 ERP 시스템 통합 프로젝트를 이끌었던 코트의 기여를 인정했습니다.
Harvard Bioscience (NASDAQ: HBIO) a annoncé la démission de la CFO et Trésorière Jennifer Cote, effective lors du dépôt du rapport 10-Q du premier trimestre 2025 de la société, prévu pour le 12 mai 2025. L'entreprise a nommé Mark Frost en tant que CFO et Trésorier par intérim.
Frost, qui conseille HBIO depuis janvier 2025, apporte plus de 30 ans d'expérience en gestion financière et exécutive. Ses précédents postes incluent des fonctions de CFO chez Fathom, Argon Medical Devices, Analogic, AngioDynamics et AMRI. Il a commencé sa carrière chez General Electric et détient un diplôme en Relations Internationales et Économie de l'Université de Colgate.
Le CEO Jim Green a exprimé sa confiance dans les capacités de Frost à diriger l'équipe financière dans l'environnement de marché difficile actuel, tout en reconnaissant les contributions de Cote, notamment dans la conduite du récent projet de consolidation du système ERP.
Harvard Bioscience (NASDAQ: HBIO) gab die Rücktritt von CFO und Schatzmeisterin Jennifer Cote bekannt, wirksam mit der Einreichung des 10-Q-Berichts des Unternehmens für das erste Quartal 2025, der bis zum 12. Mai 2025 erwartet wird. Das Unternehmen hat Mark Frost zum Interim CFO und Schatzmeister ernannt.
Frost, der seit Januar 2025 für HBIO tätig ist, bringt über 30 Jahre Erfahrung in der Finanz- und Führungskompetenz mit. Zu seinen bisherigen Positionen gehören CFO-Positionen bei Fathom, Argon Medical Devices, Analogic, AngioDynamics und AMRI. Er begann seine Karriere bei General Electric und hat einen Bachelor-Abschluss in Internationalen Beziehungen und Wirtschaft von der Colgate University.
CEO Jim Green äußerte Vertrauen in Frosts Fähigkeiten, das Finanzteam in der aktuellen herausfordernden Marktsituation zu leiten, und erkannte gleichzeitig Cotes Beiträge an, insbesondere bei der Leitung des kürzlichen Projekts zur Konsolidierung des ERP-Systems.
- Appointment of experienced interim CFO with extensive public company and healthcare sector expertise
- Smooth transition period planned with Q1 2025 report filing
- Recent completion of ERP system consolidation project for operational efficiency
- Unexpected CFO departure during challenging market environment
- Temporary leadership structure with interim CFO appointment
HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation.
Mr. Frost brings over 30 years of financial and executive-level management experience from both private and public companies. He has served as a consultant to the Company since January 2025. Mr. Frost previously served as the Chief Financial Officer of Fathom, a digital manufacturing company providing prototype and bridge production capability to accelerate new product development for Fortune 500 companies. Prior to joining Fathom, Mr. Frost was Chief Financial Officer for Argon Medical Devices, a medical devices company planning to go public in Hong Kong. Prior to Argon, Mr. Frost also served as the Chief Financial Officer for three public Healthcare companies including Analogic, AngioDynamics and AMRI. Mr. Frost began his career with General Electric, where he held a variety of finance roles over the course of fourteen years. Mr. Frost holds a BA in International Relations and Economics from Colgate University. He is also a graduate of the INSEAD Global Executive Program and GE Financial Management Program.
Jim Green, Chairman and CEO, said, “Mark is a proven financial executive with extensive experience in corporate finance and as a public company CFO. I am confident in Mark’s financial and business acumen as well as his ability to lead our finance team in a challenging market environment.”
Green continued, “Jen has been a trusted and valuable partner to our senior leadership team. She has also been instrumental in leading our finance team and in driving numerous initiatives, such as sponsoring our recent ERP system consolidation project to drive operational efficiency. I would like to wish Jen the best of luck in the next phase of her career.”
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance, growth and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic conditions, and matters relating to our ability to continue as a going concern, fund our operations, or refinance our outstanding indebtedness. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
Jim Green
President and CEO
(508) 893-3120
investors@harvardbioscience.com
FAQ
When will Harvard Bioscience CFO Jennifer Cote's resignation become effective?
Who is the new interim CFO of Harvard Bioscience (HBIO)?
What is Mark Frost's experience before joining HBIO as interim CFO?
What major project did outgoing HBIO CFO Jennifer Cote lead?
